Symposium Pediatric and Adult Neuromuscular Diseases
In light of the rapidly evolving treatment landscape for neuromuscular diseases, we would like to discuss with you this year the possibilities we have and challenges we face measuring the outcome of our patients that benefit from such therapies.
- What are relevant outcomes used in studies?
- Can we transfer them to our clinical practice and are they suitable for a day-to-day work?
- What are possible future perspectives?
- Colleagues from different medical specialities, professions, and also other Swiss reference centers have accepted to share their knowledge.
Coordination: Prof. O. Scheidegger, Prof. A. Klein, Prof. U. Fischer, Prof. P. Latzin
Program
How do we measure the treatment outcome of patients suffering from neuromuscular diseases in clinical studies and practice?
|
14.00–14.05 |
Welcome and opening remarks |
|
|
14.05–14.35 |
In pediatric patients |
|
|
14.35–15.05 |
Clinically and using PROMs |
|
|
15.05–15.35 |
Using neurophysiological techniques |
|
|
15.35–16.00 |
Coffee break |
|
|
16.00–16.30 |
Using imaging |
|
|
16.30–17.00 |
Using pneumological outcomes like lung function and sleep parameters |
|
|
17.00–17.30 |
Using wearables/nearables |
|
|
17.30 |
Closing remarks followed by an aperitif |
